Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 445

Northwestern Medicine researchers are investigating a novel stem cell therapy known as SB623 that may hold the key to improving motor function following a disabling stroke. Northwestern is currently one of only a few sites in the nation enrolling participants in a landmark study to test the safety and efficacy of adult stem cell therapy for patients with stable ischemic stroke. While the study’s primary purpose is to examine the safety of SB623 stem cells, researchers will also seek to determine whether the cells are effective in improving stroke symptoms.

SB623 is derived from genetically engineered adult bone marrow cells from a healthy adult donor. Early participants have received 2.5 million cells, but as the study progresses, the dose will escalate to 5 million and eventually 10 million cells. Since SB623 cells are allogeneic, a single donor’s cells can be used to treat many other individuals. Participants in the study will be followed for up to two years, with periodic evaluations for safety and effectiveness in the improvement in motor function.

Even at this early phase, researchers recognize the potential of stem cell therapy. Stem cell therapy may hold the key to treating a wide range of neurological disorders that currently do not have many available therapies. The participants in the trial are the University of Pittsburgh Medical Center and Stanford University School of Medicine.